Table 1. Patient Characteristics at Baseline.
Characteristic | Combined Phases 1 and 2 Patients With Ovarian Carcinoma (n = 62) |
---|---|
Age, median (range), y | 60 (46-83) |
ECOG performance status, No. (%)a | |
0 | 44 (71) |
1 | 18 (29) |
Prior lines of therapy, median (range) | 3 (1-5) |
Prior bevacizumab, No. (%) | 39 (63) |
Prior chemotherapy, No. (%)b | |
Anthracycline | 40 (65) |
Cyclophosphamide | 5 (8) |
Gemcitabine hydrochloride | 29 (47) |
Paclitaxel | 61 (98) |
Platinum | 62 (100) |
Topotecan hydrochloride | 3 (5) |
Platinum status, No. (%) | |
Resistant | 30 (48) |
Refractory | 17 (27) |
Not applicablec | 15 (24) |
tBRCA status, No. (%) | |
BRCA1 mutation | 9 (15) |
BRCA2 mutation | 2 (3) |
BRCA wild type | 49 (79) |
Unknown | 2 (3) |
HRD status, No. (%) | |
HRD positive | 22 (35) |
HRD negative | 33 (53) |
HRD unknown | 7 (11) |
PD-L1 status, No. (%)d | |
Positive | 35 (56) |
Negative | 21 (34) |
Unknown | 6 (10) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HRD, homologous recombination deficiency; PD-L1, programmed death-ligand 1; tBRCA, tumor BRCA.
Zero indicates fully active and able to perform all predisease activities without restriction; 1, restricted in strenuous activity yet ambulatory and able to do light work.
Includes chemotherapy used in more than 1 patient; those used in only 1 patient are not listed.
Includes patients with an interval free of platinum-based chemotherapy of at least 180 days but unable to receive further platinum-based chemotherapy (owing to toxic effect or allergic reaction).
Positivity was based on a combined positive score of 1 provisional cutoff by immunohistochemistry.